We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




ResearchDx Completes Service Offerings by Partnering with CompanDX

By LabMedica International staff writers
Posted on 22 Jun 2011
ResearchDx (Irvine, CA, USA) is partnering with CompanDX (Nottingham, United Kingdom) to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting.

CompanDX uses its Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. More...
ResearchDx designs, produces and validates tests ready for the market and offers turnkey solutions for companion diagnostic delivery.

The new partnership will enable clients to initiate the development of companion diagnostic tests from the earliest stages of drug development. CompanDX has developed a set of tools to deliver an understanding of the mechanism of action and biomarkers that describe patient response.

ResearchDx is a Contract Diagnostics Organization (CDO) for the diagnostic and biopharmaceutic industries. The company's primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. ResearchDx offers CLIA certified, CAP accredited high-complexity testing through its subsidiary, Pacific Diagnostics. It provides a full complement of cytogenetics, Fluorescence in situ hybridization (FISH), molecular and specialty services.

"Our partnership with CompanDX completes our service offerings," said founders of ResearchDx Dr. Philip Cotter and Dr. Mathew Moore. "CompanDX's unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process. Our customers can trust ResearchDx to meet scientific challenges with a focus on their business priorities."

Related Links:

ResearchDx
CompanDX



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.